GlassScriptPhysician profile
Vlasios S Sotirchos
NPI 1114312642
$4,391.65
in general payments reported to CMS, 2019-2025
10 companies · $3,220 in 2025
The $3,220 reported for 2025 was more than what 81% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
See the full distribution for Vascular & Interventional Radiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $255 · 2022: $95.78 · 2023: $282 · 2024: $539 · 2025: $3,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556 · Travel and Lodging: $1,485 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.77 |
| Travel and Lodging | $1,485.17 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $1,450.84 | 2025 | |
| Intera Oncology, INC | $1,391.02 | 2024-2025 | Intera |
| Boston Scientific Corporation | $681.42 | 2022-2024 | Obsidio, Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial), Ekosonic |
| Argon Medical Devices, INC. | $289.58 | 2025 | Clot Management, Option Ivcf, Clot Management |
| Inari Medical, INC. | $169.03 | 2021 | |
| Bard Peripheral Vascular, INC. | $145.07 | 2025 | |
| Penumbra, INC. | $131.16 | 2023 | Ruby Coil |
| Medtronic, INC. | $85.90 | 2021 | |
| Trisalus Life Sciences, INC. | $33.34 | 2025 | Trinav Infusion System |
| Abbott Laboratories | $14.29 | 2023 | Perclose Prostyle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vlasios Sotirchos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.